Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis.

CONCLUSIONS: This meta-analysis showed that patients who progressed on first-line trastuzumab-based therapy but of whom trastuzumab was continued in second-line and added to chemotherapy did not show longer OS or a higher ORR compared to patients receiving second-line chemotherapy-alone. However, PFS was prolonged and trastuzumab was not associated with additional safety concerns. In absence of available second-line HER2-targeted agents, a large prospective RCT should investigate if continuation of trastuzumab might be an attractive strategy, as this meta-analysis was mostly based on non-randomized studies and a RCT with a small sample size. PMID: 30264641 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30264641?dopt=Abstract

Source: Acta Oncologica - September 28, 2018 Category: Cancer & Oncology Authors: Ter Veer E, van den Ende T, Creemers A, de Waal L, van Oijen MGH, van Laarhoven HWM Tags: Acta Oncol Source Type: research